Which of these elite biotechs is the better buy right now?
News & Analysis: Amgen
These charts show there's a new Amgen emerging.
These cancer drug developers could report market-moving news soon.
These three biotech stocks could be prime comeback candidates.
AMGN earnings call for the period ending March 31, 2019.
The first three months of the year weren't nearly as positive as investors had hoped for.
If you thought Monday was exciting, wait until you see what's on the slate for the rest of the week.
Which biotech giant is the smarter choice for investors today?
Its size, catalog, and pipeline give it strengths that are hard to beat.
These two are intertwined in a legal tango that could get messy.